Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children-Reference-Cited by-同舟云学术

Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children

Published:2009-10-07 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ni Chroinin Muireann¹,Greenstone Ilana²,Lasserson Toby J³,Ducharme Francine M⁴⁵

Affiliation:

1. Cork University Hospital; Division of Children's Services; Cork Ireland

2. Montreal Children's Hospital; 2300 Tupper St Montreal Canada H3H 1P3

3. The Cochrane Collaboration; Cochrane Editorial Unit; 11-13 Cavendish Square London UK W1G 0AN

4. University of Montreal; Department of Paediatrics; Montreal Québec Canada

5. CHU Sainte-Justine; Research Centre; Montreal Canada

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005307.pub2/fullpdf

Reference542 articles.

1. Combined salmeterol/fluticasone propionate versus fluticasone propionate alone in mild asthma;Boonsawat;Clinical Drug Investigation,2008

2. The efficacy and safety of Seretide/Advair once daily (50/100mcg) compared fluticasone propionate (100mcg) once daily and placebo as initial maintenance therapy in mild asthma;Boonsawat;American Journal of Respiratory & Critical Care Medicine,2004

3. Seretide/Advair once daily (50/100mcg) is effective in patients with mild asthma;Goryachkina;American Journal of Respiratory & Critical Care Medicine,2004

4. SAS30023 A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects http:www.ctr.gsk.co.uk 2004

5. Chuchalin AG Ovcharenko SI Goriachkina LA Sidorenko IV Tsoi AN Formoterol (Oxis®) Turbuhaler® plus budesonide turbuhaler® is more effective than current non-steroid therapy and budesonide alone in mild to moderate asthma in Russia Annual Thoracic Society 97th International Conference; San Francisco CA, May 18-23 2001

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study protocol: A comparison of mobile and clinic‐based spirometry for capturing the treatment effect in moderate asthma;Clinical and Translational Science;2023-09-08

2. Modelling ASthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: A time‐to‐event analysis of randomized clinical trials;British Journal of Clinical Pharmacology;2023-07-06

3. S2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023;Pneumologie;2023-07-05

4. Bronchial asthma: focus on adherence to inhaled therapy;Meditsinskiy sovet = Medical Council;2022-10-14

5. Pretreatment Alveolar Nitric Oxide Levels Predict Improvement of Pulmonary Function 1 Year Following Anti-Asthma Treatments in Patients with Inhaled Corticosteroid-Naïve Asthma;International Archives of Allergy and Immunology;2022